Analysts/Institutional Investor Meet/Con. Call Updates

Date : June 18, 2026 To, To, The Corporate Relations Department The Listing Department The BSE Limited The National Stock Exchange of India Limited Department of Corporate Services Exchange Plaza, Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400001 Mumbai – 400051 Ref:- Scrip ID: - 500126 Ref:- Scrip Code:- PGHL Dear Sir / Madam, Sub: Analysts/Institutional Investors – Outcome – Recording and Transcript This has reference to the virtual connect with analysts/ institutional investors held today, Thursday, June 18, 2026, at 2:30 p.m. (IST) and concluded on at 3.48 pm. Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a link to the recording of the meeting is made available on the website of the Company at: https://www.pghealthindia.com/investors/#analyst-investors-meeting. Further, enclosed below is the transcript of the above meeting with analysts/ institutional investors, copy of the same is also made available on the website of the Company. This is for your record and appropriate dissemination. For Procter & Gamble Health Limited Zeal Rupani Company Secretary Procter & Gamble Health Limited Investors & Analysts’ Call June 18, 2026 Start Time: 2:30 P.M. End Time: 3:48 P.M. Speakers: Mr. Milind Thatte, Managing Director Mr. Shashank Srowthy, Director (Executive) & Chief Financial Officer Ms. Zeal Rupani, Company Secretary Ms. Zeal Rupani: Good afternoon, everyone, and welcome to Procter & Gamble Health Limited’s Investors and Analysts Call. I am Zeal Rupani, Company Secretary of the company. Thank you for joining us. Today we will begin with presentation by the management of the company on the company's performance, results, strategies and business outlook. We have received questions submitted by the participants at the time of registration of the call. The management will address the questions received after the presentation. Let me introduce our presenters for today. We have on the call Milind Thatte, Managing Director of the Company and Shashank Srowthy, Chief Financial Officer & Executive Director. All participants are placed on mute and can participate in the Listen only mode. Please note that during the course of the call, the presentation and information shared by the management may include forward-looking statements. This may include words, phrases, numbers that set forth anticipated results based on management’s current plans and assumptions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and uncertainties that may cause results to differ materially from those expressed or implied in those statements. The Company cautions investors that any such forward-looking statements are not guarantees of future performance and that actual events or results may differ materially from those statements. Actual events or results may differ materially because of factors that affect international businesses and global economic conditions, as well as matters specific to the Company and the markets it serves. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, except to the extent required by law. With that, I now hand over to Milind, for the management presentation. Mr. Milind Thatte: Good afternoon, everyone. Thank you for taking out the time to join us for this connect today. It is our pleasure to share with you the work that we have been leading at Procter and Gamble Health Ltd., and what we have accomplished in the last fiscal year 2025-2026. Today we will cover the following 1. Business results for the year 2. Our strategy and fiscal year update 3. Some long-term trends, and 4. The industry landscape. Let me start by taking you through the fiscal year results. We delivered a strong year with consistent top-line and bottom-line growth. We continued to invest across the value chain to address the evolving needs of our consumers, patients, and healthcare professionals commonly referred as HCPs. These include superior innovations that are backed by science to help our consumers & patients live healthier and more vibrant lives. It also includes  communication initiatives  a more strengthened go-to-market and  supply chain capabilities. For the 12-month fiscal year ended March 31, 2026, we reported sales of close to ₹1400 crore, that is up 16% versus the comparable 12-month period last year. Profit after tax was ₹327 crores, which is up 30% versus the comparable period last year. These results and value creation for all our stakeholder are driven by our integrated growth strategy, that comprises of: 1. A portfolio of quality, trusted and highly recommended consumer healthcare products in categories where clinical performance matters. 2. Superiority across product, package, brand communication to consumers and HCPs, retail execution at Pharmacy and Chemists, at the right Value 3. Productivity… to enable superiority and deliver results at the levels expected 4. Constructive disruption to stay ahead, and 5. And an organization that is fully engaged, enabled and excited to serve consumers and patients. We continue to invest in creating superior propositions for our consumers & patients, as well as partners including HCPs, Chemists and Distributors…along with relevant innovation, powerful brand campaigns across every touchpoint. We also continue to improve in-market execution across all channels and platforms. We remain confident that the best path forward is to double-down on this strategy that has enabled strong results over the last five years, and which is the foundation for balanced growth and value creation. Now, let me take you through some highlights of how this strategy comes to life. Our robust portfolio combines science with deep consumer and patient understanding. We are committed to deliver high-quality, trusted products to consumers and patients for a healthy lifestyle and improved quality of life. In the categories we operate – clinical performance plays a significant role in brand choice, so our focus remains on offering irresistible superiority to our consumers and patients, and HCPs. Our portfolio includes a diverse offering of trusted and science-backed vitamins, minerals, and supplement products, across categories including Vitamin B, Iron, Vitamin E, Vitamin B Complex, Nasal Care and Omega-3. Our recognized brands such as Neurobion, Livogen, Evion, Seven Seas, Polybion and Nasivion have been helping generations of Indians live healthier and more vibrant lives. The next element of our strategy is Superiority. Our Brand SKUs have been catering to strong, loyal and large consumer & patient bases. We know that, to continue winning with these consumers and patients, and to attract new consumers and patients to our portfolio, we need to deliver irresistible superiority. Therefore, we invest in our brands to provide them the best-in-class healthcare solutions to address their unmet needs. Our strategic choice of superiority is reflected through innovation across the five vectors of superiority, that are interlinked and work together to deliver results. This includes: Superior performing products in superior packaging that provide noticeably better benefits to consumers and patients. Superior Brand Communications that help patients and HCPs learn more about these products, their benefits and the needs they fulfil Superior Retail Execution, that enables our consumers and patients to experience these products in store, as well as online on digital platforms, at the right value. Consumers and patients are at the core of what we do, and we are always listening to what they need. The insights we garner are incorporated across our product formulations, packaging, and communication to better serve their needs. We look at superiority as a never-ending challenge and opportunity, and therefore continue adapting our [Showing first 8,000 characters — download PDF for full document]